Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on β-cell rest? by Jansen, A. (Annemarie) et al.
Journal of Autoimmunity (1996) 9, 341–348
Effect of Prophylactic Insulin Treatment on the Number
of ER-MP23+ Macrophages in the Pancreas of NOD Mice.
Is the Prevention of Diabetes Based on â-cell Rest?
Annemarie Jansen1, Judith G. M. Rosmalen1, Françoise Homo-Delarche2,
Mireille Dardenne2 and Hemmo A. Drexhage1
1Department of Immunology, Erasmus
University Rotterdam, The Netherlands
2CNRS URA 1416, Hôpital Necker, Paris,
France
Prophylactic insulin treatment has been shown to have beneficial effects in
type 1 diabetes, both in humans and in various animal models of the disease.
In experimental models, the protective effect of prophylactic insulin treatment
was observed in two parameters: (1) progression of insulitis and (2) diabetes
incidence. The mechanism of protection still remains to be investigated. We
therefore analysed by immunohistochemistry the effect of prophylactic insulin
treatment vs placebo treatment (from 4 to 13 weeks of age) on ER-MP23+
macrophage infiltration in and around pancreatic islets in the non-obese
diabetic (NOD) mouse, a spontaneous model for type 1 diabetes. BALB/c mice
were used as diabetes-free controls. Using conventional haematoxylin–eosin
staining, we detected a protective effect of prophylactic insulin treatment in
NOD females on the lymphocytic insulitis, significant at 13 weeks, but not at
9 weeks of age. However, when assessed by immunostaining for early
infiltration of ER-MP23+ macrophages around islets, the reduction in severity
of insulitis could already be detected as early as 9 weeks of age. With regard
to the early accumulation of ER-MP23+ cells, we observed that their numbers
per mm2 surface area of the exocrine pancreas and per ìm at the circumference
of the islet were higher in placebo-treated NODs (197±13.8 and 14±0.9,
respectively) as compared to age-matched BALB/c mice (123.1±7.1 and
3.5±0.9, respectively). Prophylactic insulin treatment of NODs lowered the
attraction of ER-MP23+ macrophages to the exocrine pancreas and to the
circumference of the islets (156.3±8.5 and 7.9±1, respectively). Interestingly
also, the islet size was found to be larger in placebo-treated NODs (51% was
larger than 10 ìm2) than in age-matched BALB/c mice (9% larger than
10 ìm2). Prophylactic insulin treatment of NODs reduced their islet size to
sizes found in the control BALB/c strain. In conclusion, the decrease in islet
size by early insulin administration, and the lower attraction of ER-MP23+
macrophages to the islets are morphological indications that prevention of
diabetes development by prophylactic insulin treatment results from a down-
regulation of islet metabolism and growth, with a concomitant decline in the
release of islet factors attracting macrophages. © 1996 Academic Press Limited
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Introduction
Insulin-dependent diabetes mellitus (IDDM) is cur-
rently believed to be an autoimmune disorder which
causes complete destruction of the insulin-producing
cells, the â-cells of the islets of Langerhans [1–3]. The
natural history of IDDM or type 1 diabetes indicates a
prolonged period termed ‘pre-diabetes’ with no evi-
dence of glucose intolerance, while an active process,
slowly destroying â-cells, is underway. The clinical
symptoms of hyperglycaemia are recognized when
the â-cell mass has been reduced below 80% of the
original [2, 3]. Insulin administration at this time not
only corrects the hyperglycaemia, but is also associ-
ated with the recovery of endogenous insulin produc-
tion, which is called the ‘honeymoon phase’ of IDDM
[4]: the pancreatic function may therefore improve
when the â-cells are relieved of hyperglycaemic stress.
However, such remissions are usually not permanent.
More recently, the improvement of â-cell function has
been confirmed in a randomized trial of intensive
insulin therapy in newly diagnosed IDDM patients,
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using a closed-loop glucose instrument, the Biostator,
during the induction phase of the treatment [5]. More-
over, recurrent exposure to the Biostator was shown to
decrease ICA and IAA levels [6], suggesting that the
autoimmune process may cease before total â-cell
destruction has occurred.
Long-term goals of type 1 diabetes research have
been to develop strategies for early identification and
prevention of IDDM. It has been shown that prophy-
lactic insulin treatment of subjects at high risk of
developing IDDM significantly delayed the onset of
diabetes [7, 8]. The same improvement was observed
in different animal models of type 1 diabetes, either
induced by neonatal streptozotocin [9], or the
spontaneous models, the BB rat [10–12] and the NOD
mouse [13]. In both the BB rat and the NOD mouse
prophylactic insulin treatment not only prevented
spontaneous disease, but transfer of diabetes to young
pre-diabetic animals was also inhibited [14, 15].
In each case slowing of the insulitis process was
observed, the mechanism of which still remains to be
elucidated. Several possible mechanisms have been
proposed in the literature, involving actions on â-cell
metabolism and/or the immune system: First, slow-
ing of the insulitis process could be the result of a
specific tolerance induction towards insulin by the
subcutaneous administration of exogenous insulin,
thus acting as a tolerogen. A second possible mechan-
ism is the suggested immunosuppressive effect of
insulin on the immune system [16]. Furthermore, it
could also be that exogenous insulin administration
downregulates â-cell metabolism [17], and quiescent
â-cells express fewer antigens [18].
There is at present increasing evidence for a role of
macrophages at early points in the disease process, as
demonstrated by several approaches in the various
models [19–21]. In the NOD mouse, we reported that
insulitis is preceded by enlargement of the perivascu-
lar area and endothelial swelling of the islet vascula-
ture, in combination with an accumulation of macro-
phages, more specifically ER-MP23+, MHC-class II+
macrophages with dendritic morphology, and
MOMA1+ macrophages [22–24]. Both cell types were
the first to accumulate around the islets, before any
lymphocyte infiltration. Moreover, high numbers of
ER-MP23+ dendritic shaped cells were also detected
in the exocrine pancreas before and during the
insulitis process in NOD mice. It is likely that these
macrophages play a role in the presentation of islet
cell antigen to T-cells. After initial accumulation of
APCs around the islets, the classical lymphocytic
para/peri-insulitis developed.
We thus hypothesized that if prophylactic insulin
treatment induces â-cell rest, resulting in a reduction
of autoantigen expression [18, 25] and release of
pro-inflammatory factors from the â-cells, lower num-
bers of macrophages should be attracted around the
islets at early stages of the disease, before any lym-
phocyte infiltration. In addition, such treatment might
also have measurable effects on â-cell mass and â-cell
insulin content. We therefore analysed the effects of
prophylactic insulin treatment on the size of the islets
of Langerhans, the early accumulation of ER-MP23+
macrophages around the islets and in the exocrine
pancreas and the development of para/peri-insulitis
in the NOD mouse.
Materials and Methods
NOD mice and BALB/c mice
Female NOD mice were bred and kept at the facilities
of Hôpital Necker, Paris, France, under specific patho-
gen free conditions, as has been described previously
[26]. They were given free access to food and water.
Under these conditions the prevalence of diabetes in
females was around 80% at 30 weeks of age. BALB/c
mice were bred and kept at the facilities of the
Department of Immunology, Erasmus University, the
Netherlands.
Insulin treatment
Thirty-three female NOD mice from the Paris colony
were divided into two experimental groups: (1) 14
were treated with Protamine-Zinc-insulin (Organon,
Oss, The Netherlands), from 4 to 6 weeks of age with
0.25 U insulin per day; from the 7th week onwards
with 0.50 U insulin per day; (2) 19 served as controls
and were treated with the same quantity of vehicle
fluid (placebo). The above described treatment
schedule is very similar to the protocol which induced
significant reduction in diabetes incidence in the
study described by Atkinson and coworkers [13].
However, we did not increase the dosage of insulin
after the 10th week of age to 0.75 U insulin/day, since
some mice became severely hypoglycaemic on this
dosage of insulin and a few had already died in a
previous experiment. All mice were weighed and
assessed for hypoglycaemia at 3, 6, 9 and 13 weeks of
age. Blood glucose levels were evaluated using
Haemoglukotest test-tapes and quantitatively
measured using colorimetry by Reflolux (Boehringer-
Mannheim). Animals with glycaemia above 11 mmol
were classified as overtly diabetic. We observed that
prophylactic insulin treatment until 13 weeks of age
did not alter the growth of the NOD females as
compared to the placebo-treated group. Mice that
became diabetic in each group during the time of the
study were not included in immunohistochemical
analysis.
Preparation of the pancreases
At the age of 9 weeks 6 NOD females from the two
experimental groups (insulin vs placebo) were killed
by cervical dislocation after rapid retro-orbital punc-
ture. For detailed immunohistochemistry pancreases
were removed, embedded in Tissue-tek and frozen in
n-hexane on dry-ice chilled alcohol. Tissues were
stored at −80°C until immunohistochemistry was
performed.
The remaining NOD females from both experimen-
tal groups were killed at 13 weeks of age, and their
pancreases prepared for scoring of lymphocytic
insulitis only. They were excised and fixed in Bouin’s
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Fluid, followed by 10% formalin, and were processed
for paraffin embedding. Specimens were then sec-
tioned (4 ìm) at four noncontiguous levels (4–50 ìm
apart). For control, four BALB/c mice were killed at 9
weeks of age. Pancreases of these animals were also
prepared for immunohistochemistry.
Lymphocytic insulitis
Lymphocytic insulitis was assessed following
haematoxylin–eosin (H+E) staining by scoring every
islet separately in one of the following classes: (a)
normal islet: lymphocytes are not visible on H+E
staining at the edge of the islet; (b) para/peri-insulitis:
lymphocytes visible at one side or surrounding the
islet; (c) infiltrative insulitis: lymphocytes detectable
infiltrating the islet, islet structure disturbed.
Monoclonal and polyclonal antibodies used to
identify different types of macrophages and
â-cells
ER-MP23 [22], used to identify MHC-class II+ APCs
was a rat–anti-mouse hybridoma culture supernatant
cultured at our department and used undiluted. This
marker was detected with horseradish peroxidase
(HRP) labelled rabbit–anti-rat immunoglobulins
(DAKO).
Guinea-pig anti-insulin polyclonal antibody
(DAKO) was used diluted 1:175 in PBS with 1% BSA,
and detected with HRP labelled rabbit–anti-guinea-
pig immunoglobulins (DAKO).
Immunohistochemistry
Immunochemistry was generally performed as
described in detail in a previous report [22]. Briefly,
the following procedure was performed. Before
sectioning, microscopic slides were coated with a
solution of 0.1% gelatine/0.01% chromiumalum in
distilled water. Thereafter, 5 ìm cryo-sections of the
stored tissue specimens were cut, dried in air over-
night, and fixed by either pararosaniline (ER-MP23) or
acetone (á-insulin).
Before exposure to first step monoclonal or polyclo-
nal antibodies, pancreases were preincubated for 10
min with 4% (v/v) normal rabbit serum. Without
washing, first step monoclonal or polyclonal antibod-
ies were applied and incubated for 1 h at room tem-
perature. Thereafter sections were washed three times
in PBS with 0.1% BSA for a total of 15 min. To
diminish background staining, 1% of normal mouse
serum was added to the HRP-labelled second step
antibodies diluted in PBS with 1% BSA. This mixture
was allowed to react for 10 min and was then applied
to the cryosections. After 30 min of incubation at room
temperature, sections were washed three times in PBS.
Thereafter the HRP label was developed for 4 min by
0.05% DAB/0.02% H2O2 dissolved in PBS. Excess
DAB was removed by running tap water. After
counterstaining by haematoxylin the slides were
dehydrated by an ethanol/xylene series and covered
with Depex.
Quantification of ER-MP23+ macrophages relative
to the circumference of the islets and of their
infiltration into the exocrine pancreas;
measurement of the surface area of the islets,
and quantification of the number of nuclei/ìm2 of
islet surface area
The number of ER-MP23+ macrophages with a visible
nucleus at the circumference of all islets without
lymphocytic para/peri-insulitis was counted in ran-
dom sections in 16–41 islets per group (six animals per
group for the insulin- and placebo-treated NODs, four
BALB/c mice). In the groups with a low variation in
the number of ER-MP23+ cells at the circumference of
the islets (BALB/c and insulin-treated NODs), a low
number of islets (n=16) sufficed for an accurate esti-
mation; in the placebo-treated NODs more islets
(n=41) were judged. Since only islets without para/
peri-insulitis could be assessed, a second series of
sections was made of the placebo-treated NODs in
order to be able to judge enough islets. The length of
the circumference of all assessed islets in the plane of
the section was measured in the same sections using
the Vidas-RT image-analysis system (Kontron Elek-
tronik GmbH/Carl Zeiss, Weesp, the Netherlands).
The number of ER-MP23+ macrophages per ìm islet
circumference of each islet was computed. In each
animal the number of ER-MP23+ cells infiltrated into
the exocrine pancreas was counted by the Vidas-RT
system in 3–4 fields not including islets. The surface
area of islets in the plane of the section was also
measured by this image analysis system.
For the measurement of the surface area of islets,
only islets without lymphocyte accumulation at the
circumference of the islet, and islets with only a few
lymphocytes present at the circumference, were meas-
ured. In BALB/c mice 32 islets were measured in four
animals, in the insulin- and placebo-treated NODs, 47
to 68 islets were assessed in six animals per group.
For the number of nuclei per ìm2 islet surface area,
22 random islets in four animals per group were
assessed, using the Vidas-RT system for counting the
nuclei, and simultaneous measurement of the
assessed islet surface area.
Statistical analysis
Comparison of the difference between the various
groups of mice for the number of ER-MP23+ macro-
phages per ìm circumference of the islet, the number
of ER-MP23+ cells/mm2 exocrine pancreas and the
insulitis classifications of the two experimental groups
were performed using the Mann–Whitney, two
sample two-tailed signed rank test. Comparison of the
number of nuclei per ìm2 islet surface area in the
different experimental groups was performed with
the two-sample, two-tailed Student’s t-test.
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Results
Severity of insulitis in insulin- and
placebo-treated NODs
Table 1 shows that infiltrative insulitis had hardly
progressed at 9 weeks of age in this cohort of animals,
affecting about 15% of the islets in both experimental
groups. Though the number of intact islets was higher
and that with para/peri-insulitis was lower in the
insulin-treated group than in the placebo-treated
group, the differences were not statistically significant
at 9 weeks of age. However, prophylactic insulin
treatment until 13 weeks of age protected the islets of
Langerhans as reflected by the significant increase in
intact islets associated with the decrease in islets with
infiltrative insulitis (P=0.02 and P=0.005, respec-
tively) in the insulin-treated group as compared to the
placebo-treated group.
Effect of insulin treatment on islets in NODs.
Comparison with islets of BALB/c mice
There was no immunohistochemical evidence for a
lower insulin content of the â-cells (fainter staining) in
any group, whether insulin- or placebo-treated NODs
or BALB/c mice. What was remarkable was that the
placebo-treated NODs—the group that developed the
most severe insulitis—presented larger islets at 9
weeks of age than age-matched BALB/c mice (Figure
1). In placebo-treated NODs 51% of the islets were
larger than 10 ìm2 in the plane of the section, and 11%
were larger than 30 ìm2; in BALB/c mice, only 9% of
the islets had a surface area in the plane of the section
larger than 10 ìm2, and no islets were found to be
larger than 30 ìm2 (difference statistically significant,
P<0.0001, using Fisher’s exact test with the cut-off
point for comparing large and small islets set at
10 ìm2).
Interestingly, insulin treatment of the NODs
reduced the number of islets with a surface area larger
than 10 ìm2 to numbers found in the BALB/c, and the
statistical difference between NODs and BALB/c mice
Table 1. Effect of prophylactic insulin treatment on the severity of insulitis (lymphocytic insulitis) in NOD
females as assessed by H+E staining
Experimental group
Insulitis n
Insulitis classification
% of islets (mean±SEM)
Intact islets Para/peri-insulitis Infiltrative
Placebo, 9 weeks 6 27.7±3.6 56.7±4.7 15.7±5.6
Insulin, 9 weeks 6 30.8±13.8 36.0±12.9 13.4±6.2
P=0.18 P=0.43 P=0.93
Placebo, 13 weeks 13 20.3±6.9 4.1±1.1 75.6±7.0
Insulin, 13 weeks 8 45.7±8.5 11.5±5.1 42.8±5.2
P=0.02 P=0.3 P=0.005
n=Number of mice.
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Figure 1. Distribution of islet sizes in placebo-treated NODs
and insulin-treated NODs, as compared to islet sizes in
BALB/c mice. The x-axis represents the islet sizes from
small to large, the y-axis the percentage of islets found with
a corresponding islet size. Note that the placebo-treated
NODs have a population of large islets, as compared to
BALB/c mice. Insulin treatment reduces islet sizes to sizes
comparable to BALB/c islets.
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disappeared (P=0.99, see Figures 1 and 2); only 9% of
the islets in insulin-treated NODs were larger than
10 ìm2 at 9 weeks of age.
Increase in islet size may be the result of â-cell
hyperplasia or hypertrophia or both. The mechanism
by which insulin treatment induces small-sized islets
is still speculative. We therefore counted the number
of nuclei per ìm2 of islet surface area. It was found
that BALB/c mice have a significantly lower number
of nuclei per surface area than NOD mice, whether
placebo-treated or insulin-treated (P<0.05, Table 2).
In spite of the reduction in islet size, insulin treat-
ment did not alter the number of nuclei per ìm2 in
islets, as compared to placebo-treated NOD mice
(P=0.18).
Effect of insulin treatment on the numbers of
ER-MP23+ macrophages in the exocrine pancreas
and around the islets in NODs as compared to
numbers in BALB/c mice
In control BALB/c mice 123.1±7.1 ER-MP23+ infil-
trating cells per mm2 exocrine pancreas were detect-
able at 9 weeks of age (Table 3). At the circumference
of the islets 3.5±0.9 ER-MP23+ dendritic-shaped cells
were found per ìm circumference. The number of
ER-MP23+ cells in placebo-treated NODs was sig-
nificantly higher than in BALB/c mice, both in the
exocrine pancreas (P=0.0006) and around islets
without para/peri-insulitis (P<0.0001) at 9 weeks of
age.
Figure 2. Islet in (a) insulin-treated female NOD of 9 weeks of age, and (b) placebo-treated female NOD of 9 weeks of age.
ER-MP23 staining, magn. 250 x (in both photos). Note the considerable difference in size of the islets. Note also that the
number of ER-MP23+ dendritic-shaped cells (dark-coloured cells) at the edge of the islet is reduced in the insulin-treated
NOD.
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Prophylactic insulin treatment significantly reduced
the number of ER-MP23+ cells in the exocrine pan-
creas (P=0.05) and around the islets (P=0.0003), as
shown in Table 3 and Figure 2. However, insulin
treatment in this study did not completely reduce the
numbers of ER-MP23+ cells in the exocrine pancreas
(P=0.015) and around the islets (P=0.0035) to levels
which were found in the control BALB/c.
Discussion
This immunohistochemical study underlines the role
of two different components in the pathogenesis of
IDDM: first, the existence of early abnormalities of the
islets of Langerhans and second, the involvement of
macrophages in the progression of insulitis in the
NOD mouse. In NOD mice, both components are
modulated by prophylactic insulin treatment.
In this study, normal NODs exhibited large-sized
islets, in contrast to BALB/c mice. NODs also showed
a higher number of nuclei per ìm2 islet surface area,
suggesting that the large-sized islets in NODs are
mainly the result of â-cell hyperplasia, in the absence
of a total outgrowth of the â-cells, giving rise to large
islets with small â-cells. The origin of this â-cell
hyperplasia in NOD mice remains to be investigated.
It is essential to note that NOD-scid mice lacking
lymphocytic insulitis also show large-sized islets at
6–9 weeks of age (to be published), underlining the
notion that a direct effect of lymphocytes on islet cell
hyperplasia can be ruled out.
Our data suggest that intrinsic islet abnormalities
are related to the NOD mouse background, and
precede the appearance of the autoimmune reaction,
classically assessed by the appearance of lymphoid
cells in the para/peri-insulitis and destructive insuli-
tis. The functional significance of the involvement of
macrophages may be analysed in the context of islet
abnormalities: more macrophages and dendritic cells
with an APC function are attracted to the pancreas in
relation to large-sized islets (to be published).
With regard to the progression of insulitis in the
NOD mouse, we confirmed the effect of prophylactic
insulin treatment in lowering the severity of destruc-
tive insulitis [13, 14]. Moreover, we showed that if the
effect of the treatment on the infiltrative lymphocytic
insulitis, as assessed by H+E staining, was not detect-
able at 9 weeks of age, it became clearly visible and
significant at 13 weeks of age. However, our more
detailed immunohistochemical analysis detected
some effects of the prophylactic insulin treatment,
already visible at 9 weeks of age, consisting of a
decrease in the number of accumulating antigen-
presenting ER-MP23+ cells around the islets and in
the pancreas, before any detectable lymphocytic
involvement.
It is also of importance to note that prophylactic
insulin treatment resulted in smaller size of the islets
of Langerhans in NOD mice (comparable to the size
found in BALB/c mice). The number of â-cells per
ìm2 islet surface area was not altered by insulin
treatment. Thus, though the size of the islets in
insulin-treated NODs was comparable to BALB/c
Table 2. Number of â-cells per ìm2 of islet surface area in the different groups of mice
Experimental groups n No. â-cellsper ìm2 (mean±SD)
Statistical significance as
compared to BALB/c mice
BALB/c 20 4.2±1.3
Placebo-treated NOD 22 5.0±0.9 P=0.03
Insulin-treated NOD 22 5.3±0.9 P=0.002
n=Number of islets analysed.
Comparison of placebo-treated versus insulin-treated NOD: P=0.2.
Table 3. ER-MP23+cell infiltration into the pancreas and around the islets in the different groups of mice
Experimental group Age n1 n2
No. ER-MP23+
cells in the exocrine
pancreas
(mean±SEM/mm2)
No. ER-MP23+
cells at the edge
of islets
(mean±SEM/ìm
circumference)
BALB/c 9 weeks 4 16 123.1±7.1 3.5±0.9
Placebo-treated NODs 9 weeks 6 41 197.0±13.8 14.0±0.9
Insulin-treated NODs 9 weeks 6 16 156.3±8.5 7.9±1.0
n1=Number of mice per group.
n2=Number of islets analysed.
Main statistical significances: exocrine pancreas: placebo-treated NOD versus BALB/c, P=0.0006; insulin-
versus placebo-treated NOD, P=0.05; around the islets: placebo-treated NOD versus BALB/c, P<0.0001;
insulin- versus placebo-treated NOD, P=0.0003.
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islets, the number of â-cells per islet was higher, the
size of the â-cells being comparable to placebo-treated
NODs. This indicated that NODs may intrinsically
have smaller â-cells than BALB/c mice. Insulin treat-
ment prevents excessive â-cell hyperplasia, but per-
mits the production of a normal amount of â-cell
mass.
The reduction in islet size was associated with a
lower number of infiltrative macrophages into the
pancreas and around and into the islets. In addition to
the role of these macrophages in initiating the autoim-
mune response, these cells may also be involved in the
regulation of the endocrine response of the islets
themselves. Also, in other organs, macrophages and
dendritic cells have been found which are able to
regulate the function of endocrine cells, for example,
the folliculo-stellate cells in the pituitary [27] and
DC-like cells and macrophages in the ovary [28] and
the testis [29]. The endocrine regulatory actions of
these cells are partly performed in a paracrine way,
but also via cell-to-cell contact [30, 31].
Our data on an effect of prophylactic insulin treat-
ment on islet sizes in the NOD mouse are similar to
results described in BB rats [18, 32], in which trans-
plantation of the insulin-producing RINm38 insuli-
noma cell line resulted in smaller islets with more
quiescent â-cells having a lower expression of â-cell
antigens. In fact, transient hyperactivity of the â-cells
has been observed in different situations leading to
IDDM [33]. This observation led to the hypothesis that
the functional state of the â-cells plays an important
role in the pathogenesis of type 1 diabetes. Indeed, a
number of in vitro experiments has shown that active
â-cells, producing high amounts of insulin, are more
susceptible to killing by immune products than are
quiescent â-cells [33, 34]. Moreover, higher â-cell
activity has been associated with higher antigen
expression [18, 25]. In vivo, the importance of a low
insulin-output by â-cells is further underlined by the
fact that in the BB rat, diazoxide administration,
which decreases insulin secretion, reduces the inci-
dence of diabetes [35]. Since insulin administration is
well known to inhibit endogenous insulin secretion
[17], essentially via an indirect neural control [36, 37],
our data also probably result from â-cell rest.
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